Tags

Type your tag names separated by a space and hit enter

Resistance to the skeletal muscle injury expressed by repeated treatment with compound A that has HMG-CoA reductase inhibitory activity.
J Toxicol Sci 2007; 32(1):9-18JT

Abstract

It has been noted that chemical-induced initial insult is sometimes no longer detected in examinations after additional consecutive treatments, suggesting that the target organs acquire resistance to the chemical toxicity. In this study, whether acquired resistance to the skeletal muscle toxicity is observed during repeated treatment of a toxic dose of Compound A that has a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity was examined. F344 male rats (7-weeks old) were given a mixed diet with 0.12% Compound A (corresponding to approximately 100 mg/kg/day) for up to 56 days. Blood samples were obtained from the tail vein periodically during the dosing period, and utilized for the measurement of creatine kinase (CK) as a marker of skeletal muscle injury. In the necropsies on Days 4, 8, 11, 28, 42 and 56, the skeletal muscles from the rectus femoris were removed for histopathology or gene expression analysis. A satellite group was provided to measure the plasma concentrations of Compound A and M1, the active metabolite of Compound A. CK levels increased from Day 9 and reached approximately 30 times those of the controls on Day 12. Histopathology of the skeletal muscle on Day 11 revealed severe necrosis of the muscle fibers. However, in spite of continuous treatments to the damaged rats, the CK levels decreased after that and returned to normal levels on Day 18. No skeletal muscle injury was observed on Days 42 and 56. There were no marked differences in the exposure levels of Compound A and M1 between Days 8 (prior to CK elevation) and 28 (post CK elevation). As for the most significant changes in the gene expression analysis for the skeletal muscle on Days 42 and 56, the probe for IkappaBa, which is known as an inhibitor for nuclear factor-kappaB (NF-kappaB), increased 2-fold compared to the control. Furthermore, an increased probe for CCAAT/enhancer-binding protein (C/EBP) delta, a transcriptional factor, and a decreased probe for cAMP-response element-binding protein (CBP)/p300, a transcriptional coactivator, were also noted significantly on Day 56. These changes in the gene expression analysis suggested suppressed NF-kappaB-mediated transactivation, which was responsible for the protective effects on the muscle injury. Based on the present findings, the resistance to skeletal muscle injury observed in this study may be attributable to the suppressed NF-kappaB-mediated transactivation, but not to the decreased exposure to toxicants.

Authors+Show Affiliations

Medicinal Safety Research Labs., Sankyo Co., Ltd, 717 Horikoshi, Fukuroi, Shizuoka 437-0065, Japan. kjtana@sankyo.co.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17327690

Citation

Tanaka, Kohji, et al. "Resistance to the Skeletal Muscle Injury Expressed By Repeated Treatment With Compound a That Has HMG-CoA Reductase Inhibitory Activity." The Journal of Toxicological Sciences, vol. 32, no. 1, 2007, pp. 9-18.
Tanaka K, Kiyosawa N, Honda K, et al. Resistance to the skeletal muscle injury expressed by repeated treatment with compound A that has HMG-CoA reductase inhibitory activity. J Toxicol Sci. 2007;32(1):9-18.
Tanaka, K., Kiyosawa, N., Honda, K., Sharyo, S., Ito, K., Teranishi, M., & Manabe, S. (2007). Resistance to the skeletal muscle injury expressed by repeated treatment with compound A that has HMG-CoA reductase inhibitory activity. The Journal of Toxicological Sciences, 32(1), pp. 9-18.
Tanaka K, et al. Resistance to the Skeletal Muscle Injury Expressed By Repeated Treatment With Compound a That Has HMG-CoA Reductase Inhibitory Activity. J Toxicol Sci. 2007;32(1):9-18. PubMed PMID: 17327690.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resistance to the skeletal muscle injury expressed by repeated treatment with compound A that has HMG-CoA reductase inhibitory activity. AU - Tanaka,Kohji, AU - Kiyosawa,Naoki, AU - Honda,Kumi, AU - Sharyo,Satoru, AU - Ito,Kazumi, AU - Teranishi,Munehiro, AU - Manabe,Sunao, PY - 2007/3/1/pubmed PY - 2007/4/6/medline PY - 2007/3/1/entrez SP - 9 EP - 18 JF - The Journal of toxicological sciences JO - J Toxicol Sci VL - 32 IS - 1 N2 - It has been noted that chemical-induced initial insult is sometimes no longer detected in examinations after additional consecutive treatments, suggesting that the target organs acquire resistance to the chemical toxicity. In this study, whether acquired resistance to the skeletal muscle toxicity is observed during repeated treatment of a toxic dose of Compound A that has a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity was examined. F344 male rats (7-weeks old) were given a mixed diet with 0.12% Compound A (corresponding to approximately 100 mg/kg/day) for up to 56 days. Blood samples were obtained from the tail vein periodically during the dosing period, and utilized for the measurement of creatine kinase (CK) as a marker of skeletal muscle injury. In the necropsies on Days 4, 8, 11, 28, 42 and 56, the skeletal muscles from the rectus femoris were removed for histopathology or gene expression analysis. A satellite group was provided to measure the plasma concentrations of Compound A and M1, the active metabolite of Compound A. CK levels increased from Day 9 and reached approximately 30 times those of the controls on Day 12. Histopathology of the skeletal muscle on Day 11 revealed severe necrosis of the muscle fibers. However, in spite of continuous treatments to the damaged rats, the CK levels decreased after that and returned to normal levels on Day 18. No skeletal muscle injury was observed on Days 42 and 56. There were no marked differences in the exposure levels of Compound A and M1 between Days 8 (prior to CK elevation) and 28 (post CK elevation). As for the most significant changes in the gene expression analysis for the skeletal muscle on Days 42 and 56, the probe for IkappaBa, which is known as an inhibitor for nuclear factor-kappaB (NF-kappaB), increased 2-fold compared to the control. Furthermore, an increased probe for CCAAT/enhancer-binding protein (C/EBP) delta, a transcriptional factor, and a decreased probe for cAMP-response element-binding protein (CBP)/p300, a transcriptional coactivator, were also noted significantly on Day 56. These changes in the gene expression analysis suggested suppressed NF-kappaB-mediated transactivation, which was responsible for the protective effects on the muscle injury. Based on the present findings, the resistance to skeletal muscle injury observed in this study may be attributable to the suppressed NF-kappaB-mediated transactivation, but not to the decreased exposure to toxicants. SN - 0388-1350 UR - https://www.unboundmedicine.com/medline/citation/17327690/Resistance_to_the_skeletal_muscle_injury_expressed_by_repeated_treatment_with_compound_A_that_has_HMG_CoA_reductase_inhibitory_activity_ L2 - http://joi.jlc.jst.go.jp/JST.JSTAGE/jts/32.9?lang=en&from=PubMed DB - PRIME DP - Unbound Medicine ER -